Pathologic analysis of sentinel lymph nodes in melanoma patients: Current and future trends
Identifieur interne : 008A89 ( Main/Exploration ); précédent : 008A88; suivant : 008A90Pathologic analysis of sentinel lymph nodes in melanoma patients: Current and future trends
Auteurs : Alice A. Roberts [États-Unis] ; Alistair J. Cochran [États-Unis]Source :
- Journal of Surgical Oncology [ 0022-4790 ] ; 2004-03-01.
Abstract
Sentinel lymph node dissection (SLND) has become the standard of care for the staging of clinically‐node negative melanomas and breast cancers. A large literature documents the efficacy of SLND in the staging of melanoma and breast cancer. The SLND has lower associated patient morbidity in comparison to elective node dissections that remove the closest regional‐draining node group. SLND has improved accuracy over traditional regional node dissection for the staging of melanoma. Currently, several multicenter trials are evaluating the prognostic significance of melanoma micrometastases in SLN detected by immunohistochemical and molecular methods. Pending trial outcome analysis, SLND has no proven effect on mortality. However, given the current oncologic emphasis on detection and removal of nodal tumor metastases, the technique has an important role in minimizing the invasiveness of tumor staging for melanoma and breast cancer. As long as lymph node metastases are used for staging solid malignancies, surgical pathologists are likely to encounter SLN excisional biopsies as a part of their routine practice. J. Surg. Oncol. 2004;85:152–161. © 2004 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/jso.20028
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000033
- to stream Istex, to step Curation: 000033
- to stream Istex, to step Checkpoint: 001F76
- to stream Main, to step Merge: 008D56
- to stream Main, to step Curation: 008A89
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pathologic analysis of sentinel lymph nodes in melanoma patients: Current and future trends</title><author><name sortKey="Roberts, Alice A" sort="Roberts, Alice A" uniqKey="Roberts A" first="Alice A." last="Roberts">Alice A. Roberts</name></author><author><name sortKey="Cochran, Alistair J" sort="Cochran, Alistair J" uniqKey="Cochran A" first="Alistair J." last="Cochran">Alistair J. Cochran</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:00C77686B4C2AA80C0B585372290144FD4600388</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/jso.20028</idno><idno type="url">https://api.istex.fr/document/00C77686B4C2AA80C0B585372290144FD4600388/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000033</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000033</idno><idno type="wicri:Area/Istex/Curation">000033</idno><idno type="wicri:Area/Istex/Checkpoint">001F76</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001F76</idno><idno type="wicri:doubleKey">0022-4790:2004:Roberts A:pathologic:analysis:of</idno><idno type="wicri:Area/Main/Merge">008D56</idno><idno type="wicri:Area/Main/Curation">008A89</idno><idno type="wicri:Area/Main/Exploration">008A89</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pathologic analysis of sentinel lymph nodes in melanoma patients: Current and future trends</title><author><name sortKey="Roberts, Alice A" sort="Roberts, Alice A" uniqKey="Roberts A" first="Alice A." last="Roberts">Alice A. Roberts</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Pathology and Laboratory Medicine, Geffen School of Medicine at UCLA, Los Angeles</wicri:cityArea></affiliation></author><author><name sortKey="Cochran, Alistair J" sort="Cochran, Alistair J" uniqKey="Cochran A" first="Alistair J." last="Cochran">Alistair J. Cochran</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Pathology and Laboratory Medicine, Geffen School of Medicine at UCLA, Los Angeles</wicri:cityArea></affiliation><affiliation><wicri:noCountry code="subField">310‐267‐2068.</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Surgical Oncology</title><title level="j" type="alt">JOURNAL OF SURGICAL ONCOLOGY</title><idno type="ISSN">0022-4790</idno><idno type="eISSN">1096-9098</idno><imprint><biblScope unit="vol">85</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="152">152</biblScope><biblScope unit="page" to="161">161</biblScope><biblScope unit="page-count">10</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-03-01">2004-03-01</date></imprint><idno type="ISSN">0022-4790</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-4790</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sentinel lymph node dissection (SLND) has become the standard of care for the staging of clinically‐node negative melanomas and breast cancers. A large literature documents the efficacy of SLND in the staging of melanoma and breast cancer. The SLND has lower associated patient morbidity in comparison to elective node dissections that remove the closest regional‐draining node group. SLND has improved accuracy over traditional regional node dissection for the staging of melanoma. Currently, several multicenter trials are evaluating the prognostic significance of melanoma micrometastases in SLN detected by immunohistochemical and molecular methods. Pending trial outcome analysis, SLND has no proven effect on mortality. However, given the current oncologic emphasis on detection and removal of nodal tumor metastases, the technique has an important role in minimizing the invasiveness of tumor staging for melanoma and breast cancer. As long as lymph node metastases are used for staging solid malignancies, surgical pathologists are likely to encounter SLN excisional biopsies as a part of their routine practice. J. Surg. Oncol. 2004;85:152–161. © 2004 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Roberts, Alice A" sort="Roberts, Alice A" uniqKey="Roberts A" first="Alice A." last="Roberts">Alice A. Roberts</name></region><name sortKey="Cochran, Alistair J" sort="Cochran, Alistair J" uniqKey="Cochran A" first="Alistair J." last="Cochran">Alistair J. Cochran</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008A89 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008A89 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:00C77686B4C2AA80C0B585372290144FD4600388
|texte= Pathologic analysis of sentinel lymph nodes in melanoma patients: Current and future trends
}}
| This area was generated with Dilib version V0.6.31. |  |